MEDICALSYSTEM(SZ:300439) Zheng Quan Ri Bao·2025-10-09 12:40Core Viewpoint - The company anticipates pressure on domestic revenue and profits in 2025 due to the full implementation of policies such as centralized procurement, disassembly of testing packages, and standardization of charging [2] Group 1: Domestic Market Strategy - The company's self-produced revenue is primarily composed of biochemical products, with most biochemical projects included in the centralized procurement scope after three rounds of inter-provincial alliance procurement for liver function, kidney function, and glucose metabolism [2] - The company plans to enhance refined management, implement large-scale production, optimize the supply chain, and increase operational efficiency to improve market share and brand influence in the immunological products sector [2] Group 2: Growth Initiatives - The company will accelerate its overseas market expansion and aims to create new performance growth points domestically through precision diagnostic products such as mass spectrometry and precise blood lipid testing [2]